The Aerogen® Solo Is an Alternative to the Small Particle Aerosol Generator (SPAG-2) for Administration of Inhaled Ribavirin
| Autor: | Keith Wilder, Saad Ghafoor, Ronald H. Dallas, Jason K Rains, Randall T. Hayden, William Humphrey, Jessica N Brazelton de Cardenas, Shane J Cross, Diego R. Hijano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adverse outcomes
ribavirin viruses lcsh:RS1-441 Pharmaceutical Science SPAG-2 lcsh:Pharmacy and materia medica 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine children Aerosol generator Medicine Small particles Adverse effect Aerogen® Solo Vibrating mesh nebulizer 030304 developmental biology 0303 health sciences business.industry allergology Ribavirin Communication virus diseases RSV infection 3. Good health chemistry Anesthesia Delivery system business 030215 immunology |
| Zdroj: | Pharmaceutics Pharmaceutics, Vol 12, Iss 1163, p 1163 (2020) |
| ISSN: | 1999-4923 |
| Popis: | Respiratory syncytial virus (RSV) is associated with adverse outcomes among immunocompromised patients. Inhaled ribavirin has been shown to improve mortality rates. The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. However, it is difficult to set up and maintain. We developed a method for delivery of this medication using the vibrating mesh nebulizer (Aerogen®). We did not observe any adverse events with this method. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|